Pharma & Bio
Lifestyle
"Premium" in the U.S. and Europe, "Volume" in Shinhung… Value Added Technology Co., Ltd.’s "Two-Track" Strategy
Value Added Technology Co., Ltd.(043150)is accelerating its global growth through a “dual-track strategy”: raising average selling prices with premium products in developed markets while increasing sa…
- 2026-09-12 08:11:02
- Kim Jinsoo
Business·Industry
[Noul Co., Ltd. Deep Seek ③] The Looming Shadow of Another Stock Offering… Year-End Is the Crucial Moment
The shadow of another capital increase is looming over the artificial intelligence (AI) diagnostics company Noul Co., Ltd.(376930). Having raised approximately 25 billion won through a capital increas…
- 2026-09-12 08:04:02
- KIM SAE-MI
Technology
Lee Byung-hwan, CEO of SkyLabs: "In Discussions with Otsuka and U.S. Partners… Aiming for FDA Approval Next Year"
#SkyLabs is taking the final steps toward entering the U.S. market.Lee Byung-hwan, CEO of SkyLabs, met with E-Daily on the 7th and stated, “Since the cuffless continuous blood pressure monitor must go…
- 2026-09-11 11:01:02
- Kim Seung-kwon
Lifestyle
'Loresibint Under Review for Approval in the U.K. Following U.S. Approval'… SamilPharmaceutical Gets Green Light to Enter 8 Trillion Won Korean Market
SamilPharmaceutical(000520)With “Lorecivivint,” a new drug for osteoarthritis for which BioSplice holds exclusive domestic distribution rights, entering the regulatory review process in the UK followi…
- 2026-09-11 10:02:02
- KIM JI-WAN
Technology
Aston Science Makes Another Run at an IPO… October Results for Stomach Cancer Vaccine Will Determine Success or Failure
Aston Science’s cancer vaccine AST-301 (HER2-ICD vaccine) is set to receive its first Phase 2 clinical trial results for stomach cancer this coming October. The company has completed patient recruitme…
- 2026-09-11 08:46:02
- NA EUN-KYUNG
Lifestyle
[Exclusive] KMPHARMACEUTICAL Co.,Ltd. Fails to Surpass 20 Billion Won in Market Cap… First Delisting from K-Bio
Following the government’s measures to tighten KOSDAQ delisting requirements, the first delisting case has emerged in the pharmaceutical and biotech industry. KMPHARMACEUTICAL Co.,Ltd., a small but st…
- 2026-09-11 08:31:02
- YU JIN-HEE
Lifestyle
Aptabio Therapeutics Inc. Takes a Gamble with APX-115 Package Deal… Next Month Will Be a Turning Point for Its “Valuation”
Aptabio Therapeutics Inc.(293780)is making a bold move with a “package deal” as it pursues the technology export of “APX-115” (Isuzinacxib), a pan-NADPH oxidase (Pan-NOX) inhibitor currently under dev…
- 2026-09-11 08:17:02
- Kim Jinsoo
Technology
MGEN Solutions and BLUEMTEC Jump as Investors Watch for Unusual Moves [K-Bio Pulse]
MGEN Solutions, whose shares began rallying before it disclosed a change in management control, and BLUEMTEC, which jumped nearly 12% without any apparent new catalyst, drew market attention on Tuesda…
- 2026-09-11 07:32:02
- NA EUN-KYUNG
Technology
MGEN SOLUTIONS Rallies Ahead of Management Control Disclosure… IlyangPharmaceutical Remains Flat Despite Negative News [Bio Market Watch]
On the 9th, in the domestic pharmaceutical, biotech, and healthcare stock market, MGEN SOLUTIONS(032790)—whose stock price had already surged prior to the announcement of a change in management contro…
- 2026-09-11 07:31:02
- NA EUN-KYUNG
Technology
Yuhan Corporation’s New Drug, Stalled for Four Years, Seeks Technology Export… “500 Billion Won Jackpot” Opportunity to Be Decided Within a Year
(Graphic: ChatGPT)
Yuhan(000100)The fate of the new drug candidate “PCS12852” (Yuhan Corporation’s development code: YH12852), which Yuhan Corporation licensed to U.S.-based Processa Pharmaceutica…
- 2026-09-10 08:16:04
- Minji Son
PHARM EDAILY
Shorts